Published in Am J Pathol on September 06, 2007
Tubulin polymerization-promoting protein (TPPP/p25) is critical for oligodendrocyte differentiation. Glia (2010) 1.19
Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci (2011) 1.18
Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther (2014) 1.09
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Acta Neuropathol (2011) 1.06
TPPP/p25 promotes tubulin acetylation by inhibiting histone deacetylase 6. J Biol Chem (2010) 1.06
Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem (2009) 1.05
Recent developments in multiple system atrophy. J Neurol (2009) 1.00
Towards translational therapies for multiple system atrophy. Prog Neurobiol (2014) 0.98
Human myelin proteome and comparative analysis with mouse myelin. Proc Natl Acad Sci U S A (2009) 0.95
Glia and alpha-synuclein in neurodegeneration: A complex interaction. Neurobiol Dis (2015) 0.93
An update on the cerebellar subtype of multiple system atrophy. Cerebellum Ataxias (2014) 0.91
The role of glia in α-synucleinopathies. Mol Neurobiol (2012) 0.89
Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells. Mol Cell Neurosci (2014) 0.86
Genetics Underlying Atypical Parkinsonism and Related Neurodegenerative Disorders. Int J Mol Sci (2015) 0.85
FAS-dependent cell death in α-synuclein transgenic oligodendrocyte models of multiple system atrophy. PLoS One (2013) 0.84
MST3 kinase phosphorylates TAO1/2 to enable Myosin Va function in promoting spine synapse development. Neuron (2014) 0.81
Multiple system atrophy: genetic or epigenetic? Exp Neurobiol (2014) 0.80
Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications. Neurotox Res (2015) 0.80
Lipid dysfunction and pathogenesis of multiple system atrophy. Acta Neuropathol Commun (2014) 0.79
Multiple system atrophy: pathogenic mechanisms and biomarkers. J Neural Transm (Vienna) (2016) 0.78
Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. Acta Neuropathol Commun (2014) 0.78
Prodegenerative IκBα expression in oligodendroglial α-synuclein models of multiple system atrophy. Neurobiol Dis (2013) 0.77
Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathol Commun (2015) 0.77
Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications. PLoS One (2016) 0.77
Exploring myelin dysfunction in multiple system atrophy. Exp Neurobiol (2014) 0.76
Oligodendroglia and Myelin in Neurodegenerative Diseases: More Than Just Bystanders? Mol Neurobiol (2015) 0.76
Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type. Neuropathol Appl Neurobiol (2016) 0.76
Novel therapeutic approaches in multiple system atrophy. Clin Auton Res (2014) 0.76
Relocation of p25α/tubulin polymerization promoting protein from the nucleus to the perinuclear cytoplasm in the oligodendroglia of sporadic and COQ2 mutant multiple system atrophy. Acta Neuropathol Commun (2014) 0.75
Multiple system atrophy: the application of genetics in understanding etiology. Clin Auton Res (2015) 0.75
α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy. Acta Neuropathol (2016) 0.75
Review: Multiple system atrophy: emerging targets for interventional therapies. Neuropathol Appl Neurobiol (2016) 0.75
Diffusion tensor imaging in the characterization of multiple system atrophy. Neuropsychiatr Dis Treat (2016) 0.75
Animal modeling an oligodendrogliopathy - multiple system atrophy. Acta Neuropathol Commun (2016) 0.75
Anti-MAG autoantibodies are increased in Parkinson's disease but not in atypical parkinsonism. J Neural Transm (Vienna) (2016) 0.75
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06
Myelination in rat brain: method of myelin isolation. J Neurochem (1973) 4.01
Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci (1989) 4.01
Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab (2004) 2.92
Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype. Cell (1987) 2.29
Myelin basic protein: a multifunctional protein. Cell Mol Life Sci (2006) 2.23
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett (1998) 2.14
A strategy for identifying gel-separated proteins in sequence databases by MS alone. Biochem Soc Trans (1996) 1.98
Immunocytochemical method to identify basic protein in myelin-forming oligodendrocytes of newborn rat C.N.S. J Neurocytol (1978) 1.94
Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron (2005) 1.73
Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol (1999) 1.65
Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci (2005) 1.63
Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J Neurosci (2003) 1.45
P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy. Acta Neuropathol (2006) 1.43
In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci (2003) 1.43
Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol (1998) 1.34
Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest (1998) 1.32
Local tissue anisotropy decreases in cerebellopetal fibers and pyramidal tract in multiple system atrophy. J Neurol (2005) 1.30
Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Exp Neurol (2006) 1.20
GPMAW--a software tool for analyzing proteins and peptides. Trends Biochem Sci (2001) 1.16
Neuronal accumulation of alpha- and beta-synucleins in the brain of a GM2 gangliosidosis mouse model. Neuroreport (2003) 1.14
alpha-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. J Neurosci Res (2000) 1.13
Myelin degeneration in multiple system atrophy detected by unique antibodies. Am J Pathol (1998) 1.10
Brain-specific p25 protein binds to tubulin and microtubules and induces aberrant microtubule assemblies at substoichiometric concentrations. Biochemistry (2002) 1.07
Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies. Neurobiol Dis (2004) 1.04
Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease. J Neuropathol Exp Neurol (2004) 1.03
Tracking the neurodegeneration of parkinsonian disorders--a pilot study. Neuroradiology (2007) 1.03
Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord (2005) 1.02
p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J Biol Chem (2004) 1.02
A brain-specific protein p25 is localized and associated with oligodendrocytes, neuropil, and fiber-like structures of the CA3 hippocampal region in the rat brain. J Neurochem (1993) 1.01
Gene expression changes in postmortem tissue from the rostral pons of multiple system atrophy patients. Mov Disord (2007) 1.00
Dynamic targeting of microtubules by TPPP/p25 affects cell survival. J Cell Sci (2004) 1.00
C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol (2000) 0.99
Study of expression of myelin basic proteins (MBPs) in developing rat brain using a novel antibody reacting with four major isoforms of MBP. J Neurosci Res (2002) 0.98
Tau and alpha-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. Acta Neuropathol (2006) 0.98
A novel brain-specific 25 kDa protein (p25) is phosphorylated by a Ser/Thr-Pro kinase (TPK II) from tau protein kinase fractions. FEBS Lett (1991) 0.97
Alpha-synuclein, Abeta and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.96
RNA on the road to myelin. J Neurocytol (2000) 0.96
The brain-specific protein TPPP/p25 in pathological protein deposits of neurodegenerative diseases. Acta Neuropathol (2006) 0.93
P25alpha/Tubulin polymerization promoting protein expression by myelinating oligodendrocytes of the developing rat brain. J Neurochem (2006) 0.92
Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease. Mol Cell Neurosci (2006) 0.92
Pick bodies in a family with presenilin-1 Alzheimer's disease. Ann Neurol (2005) 0.90
Interaction of TPPP/p25 protein with glyceraldehyde-3-phosphate dehydrogenase and their co-localization in Lewy bodies. FEBS Lett (2006) 0.87
P24, a glycogen synthase kinase 3 (GSK 3) inhibitor. Biochim Biophys Acta (2002) 0.85
p25alpha is flexible but natively folded and binds tubulin with oligomeric stoichiometry. Protein Sci (2005) 0.85
Myelin under construction -- teamwork required. J Cell Biol (2006) 0.82
Mutations in the rat myelin basic protein gene are associated with specific alterations in other myelin gene expression. Neurosci Lett (2002) 0.81
Primary involvement of the motor area in association with the nigrostriatal pathway in multiple system atrophy: neuropathological and morphometric evaluations. Acta Neuropathol (2001) 0.80
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord (2008) 5.72
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Hfq: a bacterial Sm-like protein that mediates RNA-RNA interaction. Mol Cell (2002) 5.26
Clinicopathological correlates in frontotemporal dementia. Ann Neurol (2004) 4.38
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 3.04
The pathological basis of semantic dementia. Brain (2005) 2.96
Rhabdomyolysis: a review. Muscle Nerve (2002) 2.89
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
Spider silk fibers spun from soluble recombinant silk produced in mammalian cells. Science (2002) 2.69
Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol (2004) 2.63
Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol (2005) 2.61
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord (2008) 2.48
Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol (2005) 2.40
Amyloid adhesins are abundant in natural biofilms. Environ Microbiol (2007) 2.35
Pedigree with frontotemporal lobar degeneration--motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurol (2008) 2.34
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Neuropathologic correlates of white matter hyperintensities. Neurology (2008) 2.29
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol (2005) 2.14
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol (2003) 2.09
Identification of the receptor scavenging hemopexin-heme complexes. Blood (2005) 1.97
Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci (2012) 1.95
The functional cobalamin (vitamin B12)-intrinsic factor receptor is a novel complex of cubilin and amnionless. Blood (2003) 1.91
Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation (2007) 1.88
Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem (2004) 1.84
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol (2005) 1.78
Prescribing of smoking cessation medication in England since the introduction of varenicline. Addiction (2011) 1.65
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Simultaneous glycan-peptide characterization using hydrophilic interaction chromatography and parallel fragmentation by CID, higher energy collisional dissociation, and electron transfer dissociation MS applied to the N-linked glycoproteome of Campylobacter jejuni. Mol Cell Proteomics (2010) 1.63
Cognitive, extrapyramidal, and magnetic resonance imaging predictors of functional impairment in nondemented older community dwellers: the Sydney Older Person Study. J Am Geriatr Soc (2006) 1.63
Multifidus muscle changes and clinical effects of one-level posterior lumbar interbody fusion: minimally invasive procedure versus conventional open approach. Eur Spine J (2009) 1.62
AutismKB: an evidence-based knowledgebase of autism genetics. Nucleic Acids Res (2011) 1.59
A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain (2005) 1.57
Small-vessel disease in patients with Parkinson's disease: a clinicopathological study. Mov Disord (2012) 1.56
Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci U S A (2007) 1.54
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
Can data from primary care medical records be used to monitor national smoking prevalence? J Epidemiol Community Health (2011) 1.50
A piggyBac transposon-based genome-wide library of insertionally mutated Blm-deficient murine ES cells. Genome Res (2009) 1.48
Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol (2006) 1.47
Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci (2010) 1.46
Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov Disord (2013) 1.44
FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry (2009) 1.44
C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology (2012) 1.44
P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy. Acta Neuropathol (2006) 1.43
Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain (2006) 1.43
Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain (2009) 1.42
Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol (2003) 1.41
Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. Mov Disord (2013) 1.39
Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dement Geriatr Cogn Disord (2007) 1.39
Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring. J Cell Physiol (2011) 1.36
A PiggyBac-based recessive screening method to identify pluripotency regulators. PLoS One (2011) 1.30
Bladder outlet obstruction: progression from inflammation to fibrosis. BJU Int (2010) 1.28
Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol (2003) 1.27
Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain (2002) 1.27
Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res (2006) 1.26
Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol (2008) 1.26
Amnionless function is required for cubilin brush-border expression and intrinsic factor-cobalamin (vitamin B12) absorption in vivo. Blood (2005) 1.25
Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol (2010) 1.24
Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release (2005) 1.24
Amyloid-like adhesins produced by floc-forming and filamentous bacteria in activated sludge. Appl Environ Microbiol (2008) 1.23
VEMS 3.0: algorithms and computational tools for tandem mass spectrometry based identification of post-translational modifications in proteins. J Proteome Res (2005) 1.22
Effect of long-term mobile communication microwave exposure on vascular permeability in mouse brain. Pathology (2002) 1.22
Severity-dependent expression of pro-inflammatory cytokines in traumatic spinal cord injury in the rat. J Clin Neurosci (2005) 1.21
Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol (2010) 1.21
Early expression and cellular localization of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord injury. Spine (Phila Pa 1976) (2004) 1.20
Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy. J Biol Chem (2002) 1.19
Alpha-synuclein association with phosphatidylglycerol probed by lipid spin labels. Biochemistry (2003) 1.19
Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol (2004) 1.19
Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathology. Acta Neuropathol (2008) 1.17
α-Synucleinopathy phenotypes. Parkinsonism Relat Disord (2014) 1.16
Retracted Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest (2008) 1.15
The role of decorated SDS micelles in sub-CMC protein denaturation and association. J Mol Biol (2009) 1.14
Curli functional amyloid systems are phylogenetically widespread and display large diversity in operon and protein structure. PLoS One (2012) 1.14
Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol (2001) 1.12
Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain (2005) 1.12
Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med (2005) 1.11
A homozygous mutant embryonic stem cell bank applicable for phenotype-driven genetic screening. Nat Methods (2011) 1.11
Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol (2003) 1.10
A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol (2010) 1.10
Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radic Biol Med (2006) 1.10
Utilizing ion-pairing hydrophilic interaction chromatography solid phase extraction for efficient glycopeptide enrichment in glycoproteomics. Anal Chem (2010) 1.10
Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov Disord (2002) 1.10
Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. Mov Disord (2002) 1.09
Characterization of gel-separated glycoproteins using two-step proteolytic digestion combined with sequential microcolumns and mass spectrometry. Mol Cell Proteomics (2004) 1.09
Multichannel monolithic quartz crystal microbalance gas sensor array. Anal Chem (2009) 1.09
Loss of miR-29b following acute ischemic stroke contributes to neural cell death and infarct size. J Cereb Blood Flow Metab (2013) 1.08
An enzymatic deglycosylation scheme enabling identification of core fucosylated N-glycans and O-glycosylation site mapping of human plasma proteins. J Proteome Res (2007) 1.07
A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats. Brain (2013) 1.07
Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci (2005) 1.06
Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain (2003) 1.06
Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Mov Disord (2011) 1.05
A SAXS study of glucagon fibrillation. J Mol Biol (2009) 1.05